Table 6.
Correspondence between in vitro activity and clinical efficacy in individual tumors
| In vitro results | Clinical results | |
|---|---|---|
| Primary | Carboplatin/taxol | |
| S/S | S | |
| R/S | S | |
| R/R | R | |
| R/R | R | |
| R/R | R | |
| R/R | R | |
| Carboplatin | ||
| R | R | |
| Recurrent | Carboplatin/taxol | |
| S/S | S | |
| R/S | R | |
| S/S | S | |
| S/R | R | |
| R/R | R | |
| R/R | R | |
| R/R | R | |
| R/R | R | |
| R/R | R | |
| R/R | R | |
| R/R | R | |
| Cisplatin/adriamycin | ||
| R/R | R | |
| S/S | S | |
| S/S | S | |
| S/S | S | |
| R/R | R | |
| R/R | R | |
| Carboplatin | ||
| R | R | |
| R | R | |
| Carboplatin/gemcitabine | ||
| R/R | R | |
| R/R | R | |
| Carboplatin/taxol/gemcitabine | ||
| R/R/R | R | |
| R/R/R | R | |
S, sensitive; R, resistant